Article Text

Research paper
Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage
  1. Olivier Bousiges1,
  2. Stephanie Bombois2,
  3. Susanna Schraen3,
  4. David Wallon4,
  5. Muriel Muraine Quillard5,
  6. Audrey Gabelle6,
  7. Sylvain Lehmann7,
  8. Claire Paquet8,
  9. Elodie Amar-Bouaziz9,
  10. Eloi Magnin10,
  11. Carole Miguet-Alfonsi11,
  12. Xavier Delbeuck2,
  13. Thomas Lavaux12,
  14. Pierre Anthony13,
  15. Nathalie Philippi13,
  16. Frederic Blanc13
  17. For the ePLM network and collaborators
  1. 1Laboratory of Biochemistry and Molecular Biology, and CNRS, Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), University Hospital of Strasbourg, Strasbourg, Alsace, France
  2. 2Université Lille Nord de France, DISTALZ, Memory Center, Lille, France
  3. 3UMR-S 1172 – JPArc-Centre de recherches Jean-Pierre Aubert Neurosciences et Cancer and CHU Lille, UF Neurobiologie, Université Lille, Lille, France
  4. 4Department of Neurology, Rouen University Hospital, Rouen, France
  5. 5Department of Biochemistry Laboratory, Rouen University Hospital, Rouen, France
  6. 6CMRR (Memory Resources and Research Centre), Department of Neurology, CHU de Montpellier, HôpitalGui de Chauliac, Montpellier, France
  7. 7Laboratoire de Biochimie et Protéomique Clinique, CHU de Montpellier and Université de Montpellier, IRMB, CRB, Montpellier, France
  8. 8CMRR (Memory Resources and Research Centre) Paris Nord Ile de France and Histologie et Biologie du Vieillissement, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal APHP, INSERM U942, Université Paris Diderot, Paris, France
  9. 9Service de Biochimie et Biologie moléculaire, GH Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France
  10. 10Department of Neurology, Centre Mémoire Ressources Recherche Besançon Franche-Comté, CHU de Besançon, Besançon, France
  11. 11Laboratoire de pharmacologie clinique, CHU de Besançon, Besancon, France
  12. 12Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France
  13. 13Neuropsychology Unit, Neurology Service, and CNRS, ICube laboratory UMR 7357 and FMTS, team IMIS/Neurocrypto, University Hospital of Strasbourg, CMRR (Memory Resources and Research Centre), Geriatrics Day Hospital, Geriatrics Service, Strasbourg, France
  1. Correspondence to Dr Olivier Bousiges, Laboratory of Biochemistry and Molecular Biology, and CNRS, Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), University Hospital of Strasbourg, UMR7364, Strasbourg, France; olivier.bousiges{at}


Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.

Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients.

Results In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups<pro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 levels were unaltered in patients with DLB (pro-DLB and DLB-d).

Conclusions Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181 were the best biomarkers to discriminate between AD and DLB, whatever the stage of disease.

Statistics from


  • Contributors OB and FB: study concept, design and supervision; FB, NP and PA: selection of patients from Strasbourg; OB and TL: analysis and interpretation of all data. SB: selection of patients from Lille; SS and XD: analysis of CSF assays of patients from Lille; DW: selection of patients from Rouen; MMQ: analysis of CSF assays of patients from Rouen; AG: selection of patients from Montpellier; SL: analysis of CSF assays on patients from Montpellier; CP: selection of patients from Paris; EA-B: analysis of CSF assays of patients from Paris; EM: selection of patients from Besançon; CM-A: analysis of CSF assays of patients from Besançon.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.